Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy

European Journal of Haematology

Volumn 87, Issue 4, 2011, Pages 289-301

  Cornely, Oliver A ^a   Aversa, Franco ^b   Cook, Perry ^c   Jones, Brian ^d   Michallet, Mauricette ^e   Shea, Thomas ^f   Vallejo, Carlos ^g  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF PERUGIA   (Italy)

^c NEW YORK UNIVERSITY   (United States)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Aspergillosis; Candidiasis; Zygomycosis

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; STEROID; THYMOCYTE ANTIBODY; TRIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VINCA ALKALOID; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ASPERGILLUS; CANCER CHEMOTHERAPY; CANDIDA; CANDIDIASIS; COMPUTER ASSISTED TOMOGRAPHY; CRITICALLY ILL PATIENT; DIAGNOSTIC TEST; DIPODASCUS CAPITATUS; DISEASE COURSE; DRUG MEGADOSE; DRUG RESPONSE; EARLY INTERVENTION; FUNGAL COLONIZATION; FUSARIUM; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; IRON OVERLOAD; LUNG LAVAGE; MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCEDOSPORIUM; SENSITIVITY AND SPECIFICITY; SYSTEMIC MYCOSIS; TRICHOSPORON; VIRUS REACTIVATION; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOSES;

EID: 80053222265     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01682.x     Document Type: Review

References (120)

1. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. Haematologica 2010;95:644-50.
2. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010;50:1091-100.
3. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003;16:607-12.
4. Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008;68:1941-62.
5. Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 2008;36:296-313.
6. Holzheimer RG, Dralle H. Management of mycoses in surgical patients: review of the literature. Eur J Med Res 2002;7:200-26.
7. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-7.
8. Hahn-Ast C, Glasmacher A, Muckter S, Schmitz A, Kraemer A, Marklein G, Brossart P, Von Lilienfeld-Toal M. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010;65:761-8.
9. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63.
10. Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009;52:197-205.
11. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9.
12. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006;27:359-66.
13. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309-16.
14. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 1999;33:217-22.
15. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
16. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004;38:311-20.
17. Pfaller MA, Boyken LB, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. J Clin Microbiol 2008;46:3585-90.
18. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
19. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, Rinaldi M, Barton R, Veselov A, Global Antifungal Surveillance Group. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008;46:515-21.
20. Samaranayake YH, Samaranayake LP. Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. J Med Microbiol 1994;41:295-310.
21. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, Kontoyiannis DP. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009;115:4745-52.
22. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, Hachem RY, Kontoyiannis DP, Raad II. The epidemiology of candida glabrata and candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002;112:380-5.
23. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.
24. Perfect JR. Management of invasive mycoses in hematology patients: current approaches. Oncology (Williston Park) 2004;18(Suppl. 7):5-14.
25. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-75.
26. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009;48:265-73.
27. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66.
28. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR, for the I3 Aspergillus Study Group. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000;79:250-60.
29. Pappas PG. Prospective surveillance for invasive fungal infections in solid organ and stem cell transplant recipients. An overview of TRANSNET. Presented at: Focus on Fungal Infections 17, March 7-9, 2007; San Diego, CA.
30. Park BJ, Pappas P, Marr KA, Anaissie EJ, Ito J, Alexander BD, Walsh TJ, Kontoyiannis DP. Recent epidemiology of zygomycosis (ZM) among organ transplant (OTR) and stem cell transplant (SCT) recipients: results from the TRANSNET surviellance network. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007; Chicago, IL.
31. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-60.
32. Girmenia C, Pagano L, Corvatta L, Mele L, Del Favero A, Martino P, for the Gimema Infection Programme. The epidemiology of fusariosis in patients with haematological diseases. Br J Haematol 2000;111:272-6.
33. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis 2006;43:1580-4.
34. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008;52:1743-50.
35. Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005;43:1818-28.
36. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005;366:1013-25.
37. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149:2349-53.
38. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995;71:311-2.
39. Kamaluddin M, McNally P, Breatnach F, O'Marcaigh A, Webb D, O'Dell E, Scanlon P, Butler K, O'Meara A. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001;90:1204-7.
40. Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, Koukila-Kahkola P, Ruutu T. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997;19:801-8.
41. Perea S, Patterson TF. Invasive Aspergillus infections in hematologic malignancy patients. Semin Respir Infect 2002;17:99-105.
42. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359:1766-77.
43. Altes A, Remacha AF, Sarda P, Sancho FJ, Sureda A, Martino R, Briones J, Brunet S, Canals C, Sierra J. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004;34:505-9.
44. Granell M, Urbano-Ispizua A, Suarez B, et al. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol 2006;34:1435-41.
45. Sainz J, Salas-Alvarado I, Lopez-Fernandez E, et al. TNFR1 mRNA expression level and TNFR1 gene polymorphisms are predictive markers for susceptibility to develop invasive pulmonary aspergillosis. Int J Immunopathol Pharmacol 2010;23:423-36.
46. Mezger M, Einsele H, Loeffler J. Genetic susceptibility to infections with Aspergillus fumigatus. Crit Rev Microbiol 2010;36:168-77.
47. Patterson TF. Invasive mycoses: management and unmet medical needs. Curr Opin Infect Dis 2001;14:669-71.
48. de Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21.
49. Kami M, Tanaka Y, Kanda Y, et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica 2000;85:745-52.
50. Kami M, Kishi Y, Hamaki T, et al. The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients. Mycoses 2002;45:287-94.
51. Kibbler C. Defining invasive fungal infections in neutropenic or stem cell transplant patients. J Antimicrob Chemother 2005;56(Suppl. 1):i12-6.
52. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762-9.
53. Verweij PE, Mennink-Kersten MASH. Issues with galactomannan testing. Med Mycol 2006;44(Suppl.):S179-83.
54. Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. The utility of galactomannan enzyme immunoassay and (1-3) β-d-glucan in the diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 2009;47:129-33.
55. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609-22.
56. White PL, Barton R, Guiver M, et al. A consensus on fungal polymerase chain reaction diagnosis? A United Kingdom-Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections. J Mol Diagn 2006;8:376-84.
57. Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health-Syst Pharm 2009;66:1711-7.
58. Viscoli C, Paesmans M, Sanz M, Castagnola E, Klastersky J, Martino P, Glauser M, on behalf of the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis 2001;32:1532-7.
59. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
60. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
61. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, Corey L, Boeckh M. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-61.
62. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33.
63. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006;57:317-25.
64. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16.
65. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47.
66. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
67. Wingard JR, Carter SL, Walsh TJ, et al. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). Blood 2010;116:5111-8.
68. Marks DI, Kibbler C, Pagliuca A, et al. Voriconazole (VOR) versus itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009; San Francisco, CA.
69. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15.
70. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature. Rev Iberoam Micol 2003;20:121-36.
71. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3, 378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006;50:917-21.
72. Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int J Antimicrob Agents 2008;32:511-4.
73. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007;51:2587-90.
74. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003;51:45-52.
75. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008;46:150-6.
76. Torres-Rodriguez JM, Alvarado-Ramirez E, Murciano F, Sellart M. MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococcus gattii. J Antimicrob Chemother 2008;62:205-6.
77. Arikan S, Lozano-Chiu M, Paetznick V, Nangia N, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999;37:3946-51.
78. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006;50:2058-63.
79. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008;52:2305-12.
80. Fera MT, La CE, De SA. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti infect Ther 2009;7:981-98.
81. Snelders E, van der Lee HAL, Kuijpers J, Rijs AJMM, Varga J, Samson RA, Mellado E, Donders ART, Melchers WJG, Verweij PE. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008;5:e219.
82. Verweij PE, Snelders E, Kema GHJ, Mellado E, Melchers WJG. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009;9:789-95.
83. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002;40:852-6.
84. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007;356:1481-3.
85. Meneau I, Sanglard D. Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates. Med Mycol 2005;43(Suppl. 1):S307-11.
86. Hof H. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist Updat 2008;11:25-31.
87. Hof H. Will resistance in fungi emerge on a scale similar to that seen in bacteria? Eur J Clin Microbiol Infect Dis 2008;27:327-34.
88. Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, Cornely OA, Patino H, Black TA. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 2009;53:5026-34.
89. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14a-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004;48:568-74.
90. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MA. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238.
91. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60.
92. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. V.2.2009. National Comprehensive Cancer Network Web site. Available at:. Accessed January 26, 2010.
93. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, Winter J, Tallman M, Pi J, Mehta J. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451-6.
94. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease. Pharmacotherapy 2007;27:1627-36.
95. Rieger CT, Ostermann H, Kolb HJ, Fiegl M, Huppmann S, Morgenstern N, Tischer J. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients. Ann Hematol 2008;87:915-22.
96. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53:337-49.
97. Maertens J, Frere P, Lass-Florl C, Heinz W, Cornely O. Antifungal Prophylaxis in Leukemia Patients: 2009 Update of the ECIL-1 and 2 Guidelines. Leukemia net Web site. Available at:. Accessed January 26, 2010.
98. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000;110:273-84.
99. Goodrich JM, Reed EC, Mori M, Fisher LD, Skerrett S, Dandliker PS, Klis B, Counts GW, Meyers JD. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991;164:731-40.
100. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-66.
101. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-66.
102. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003;4:974-90.
103. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, Fridkin SK, Pappas PG, Warnock DW. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005;43(Suppl. 1):S49-58.
104. Maertens J, Demuynck H, Verbeken EK, Zachee P, Verhoef GE, Vandenberghe P, Boogaerts MA. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999;24:307-12.
105. Martino R, Subira M, Rovira M, Solano C, Vazquez L, Sanz GF, Urbano-Ispizua A, Brunet S, De la Camara R, for the alloPBSCT ind Infectious/Non-infectious Complications Subcommittees of the Grupo Espanol de Transplante Hematopoyetico. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116:475-82.
106. Grigull L, Beier R, Schrauder A, Kirschner P, Loening L, Jack T, Welte K, Sykora KW, Schrappe M. Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses 2003;46:441-6.
107. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006;20:485-506.
108. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995;21:361-9.
109. ® Aspergillus EIA [prescribing information]. Hercules, CA: Bio-Rad Laboratories, 2006.
110. Foy PC, van Burik J-AH, Weisdorf DJ. Galactomannan antigen enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:440-3.
111. Mennink-Kersten MASH, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004;4:349-57.
112. Maertens J, Theunissen K, Deeren D, Meersseman W, Van Eldere J. Defining a case of invasive aspergillosis by serum galactomannan. Med Mycol 2006;44(Suppl.):173-8.
113. Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007;44:1329-36.
114. Maertens J, Theunissen K, Lodewyck T, Lagrou K, Eldere JV. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007;50(Suppl. 1):2-17.
115. Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review. Chest 2010;138:817-24.
116. Glucan Assay for (1, 3)-b-d-Glucan in Serum: Fungitell™- Instructions for Use [prescribing information]. East Falmouth, MA: Associates of Cape Cod Incorporated, 2004.
117. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. b-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199-205.
118. Mennink-Kersten MA, Warris A, Verweij PE. 1, 3-b-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006;354:2834-5.
119. White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006;42:479-86.
120. Buchheidt D, Hummel M. Aspergillus polymerase chain reaction (PCR) diagnosis. Med Mycol 2005;43(Suppl. 1):S139-45.